Literature DB >> 19286458

Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses.

Marc Witmer1, Robert Danovich.   

Abstract

This report describes methods for the selection and analysis of antiretroviral resistance to HIV integrase strand transfer inhibitors (InSTIs) in cell culture. The method involves the serial passage of HIV-1 in the presence of increasing concentrations of test inhibitors, followed by the cloning and sequencing of the integrase coding region from the selected viruses. The identified mutations are subsequently re-engineered into a reference wild-type molecular clone, and the resulting replication capacity and level of drug resistance are determined relative to the wild-type virus. Here we describe examples of selection and analysis of InSTI-resistant viruses using four integrase inhibitors from three structurally distinct chemical classes; a diketo acid, two naphthyridines, and a pyrimidinecarboxamide. Each inhibitor selected an independent route to resistance. Interestingly, the shift in the IC50 required to suppress the re-engineered resistant mutant viruses closely matched the concentration of compound used during the selection of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286458     DOI: 10.1016/j.ymeth.2009.02.025

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  5 in total

1.  Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.

Authors:  Ashley N Brown; Jonathan R Adams; Dodge L Baluya; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.

Authors:  Kendra E Hightower; Ruolan Wang; Felix Deanda; Brian A Johns; Kurt Weaver; Yingnian Shen; Ginger H Tomberlin; H Luke Carter; Timothy Broderick; Scott Sigethy; Takahiro Seki; Masanori Kobayashi; Mark R Underwood
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

3.  Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.

Authors:  Signe Fransen; Soumi Gupta; Arne Frantzell; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

4.  Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.

Authors:  Krishan K Pandey; Sibes Bera; Ajaykumar C Vora; Duane P Grandgenett
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

5.  Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.

Authors:  Signe Fransen; Soumi Gupta; Robert Danovich; Daria Hazuda; Michael Miller; Marc Witmer; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.